BEDAQUILINE SHOULD ONLY BE USED IN COMBINATION WITH AT LEAST 3 OTHER DRUGS TO WHICH THE PATIENT'S MDR-TB ISOLATE HAS BEEN SHOWN TO BE SUSCEPTIBLE IN VITRO. IF IN VITRO TESTING RESULTS ARE UNAVAILABLE, TREATMENT MAY BE INITIATED WITH BEDAQUILINE IN COMBINATION WITH AT LEAST 4 OTHER DRUGS TO WHICH THE PATIENT'S MDR-TB ISOLATE IS LIKELY TO BE SUSCEPTIBLE. THROUGHOUT TREATMENT WITH, AND FOLLOWING THE LAST INTAKE OF SIRTURO, PATIENTS SHOULD CONTINUE TO TAKE THEIR COMPANION DRUGS AS DIRECTED.
RECOMMENDED DOSE: WKS 1-2: 400 MG ONCE DAILY WITH FOOD, WKS 3-24: 200 MG, 3 TIMES PER WEEK (WITH AT LEAST 48 HOURS BETWEEN DOSES) FOR A TOTAL DOSE OF 600 MG PER WK. TOTAL DURATION OF TREATMENT IS 24 WEEKS.